Articles in Press
Value in Health offers readers the opportunity to access complete articles (Articles in Press) to be published in upcoming issues of Value in Health. Current Articles in Press can be found at: http://www.valueinhealthjournal.com, by clicking the “Articles in Press" tab.
Articles that appear in Articles in Press can be found in future issues of Value in Health listed below. All articles in these future issues have been accepted for publication, and currently may be at any stage in the post-acceptance process, which include copy-editing, typesetting, author review, revisions, and pre-electronic production, with articles in earlier issues appearing sooner than articles in later issues. These accepted articles appear in Articles in Press only after completing the post-acceptance process and remain for viewing until approximately one month prior the hard copy release date (Note: The timeframe from when an article is accepted, and appears and remains in Articles in Press are approximate, pending submission to publisher, extent of typesetting, author turn-around times, revisions, etc. Thus, some accepted articles that appear below may not appear in Articles in Press).
Value in Health 2013 Volume 16
ViH-11-2012-0434-OM.R2 An integrated approach to evaluating alternative risk prediction strategies: a case study comparing alternative approaches for preventing invasive fungal disease Z. Sadique, R. Grieve, D.A. Harrison, M. Jit, E. Allen, K.M. Rowan, FIRE Study Investigators
ViH-11-2012-0433-OM.R2 MIFAMURTIDE FOR HIGH-GRADE, RESECTABLE, NON-METASTATIC OSTEOSARCOMA FOLLOWING SURGICAL RESECTION: A COST-EFFECTIVENESS ANALYSIS Sukhvinder Johal, Stephen Ralston, Christopher Knight
ViH-03-2013-0124-OM.R1 A CPRD analysis of antidepressant treatment patterns and healthcare costs in Generalized Anxiety Disorder Julien Chollet, Delphine Saragoussi, Emilie Clay, Clément François
ViH-12-2012-0463-OM.R3 Understanding the economic burden of non-severe nocturnal hypoglycemic events: impact on work productivity, disease management, and resource utilization Meryl Brod, PhD, Michael Wolden, MSc, Torsten Christensen, MSc, Donald M. Bushnell, MA
ViH-03-2013-0108-OM.R2 ASSESSMENT OF PRO LABELS CLAIMS GRANTED BY THE FDA AS COMPARED TO THE EMA (2006–2010) Carla DeMuro, MS, Marci Clark, PharmD, Lynda Doward, MSc, Emily Evans, BS, Margaret Mordin, MS. Ari Gnanasakthy, MSc
ViH-03-2013-0135-OM.R2 Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: Lessons learned from a feasibility study in the UK Paul Swinburn,* MRes, Andrew Lloyd, DPhil, Kristina Boye, PhD, Emily Edson-Heredia, MPH, Lee Bowman, PhD, Bas Janssen, PhD
ViH-11-2012-0415-PS.R3 A pilot study of multi-criteria decision analysis for valuing orphan medicines Jon Sussex; Pierrick Rollet; Martina Garau; Claude Schmitt; Alastair Kent
ViH-02-2013-0078-BR.R1 Validation of models that estimate the cost-effectiveness of improving patient adherence Afschin Gandjour, MD, PhD, MA
LETTERS TO THE EDITOR
ViH-08-2013-0318-LE Letter to the Editor to "Wielage et al., The Cost-effectiveness of Duloxetine in Chronic Low Back Pain: A US Private Payer Perspective. Value in Health 16 (2013) 334-344" Hiltrud Liedgens, PhD, MaHE and Rainer Henske
ViH-09-2013-0389-LE The Cost-Effectiveness of Duloxetine in Chronic Low Back Pain: a US Private Payer Perspective - Author Response to Letter to the Editor Ronald C. Wielage, MPH, Megha Bansal, MA, J. Scott Andrews, PharmD, Madelaine M. Wohlreich, MD,Robert W. Klein, MS, Michael Happich, PhD
Also in this issue is a Letter to the Editor concerning a previous article on cost-effectiveness of dulozetine in chronic low back pain, and a response from the author.
Value in Health Main